Abstract
We have tested a new type of immunoliposomes which may effectively mediate the targeting of enzymes to be used for site-specific prodrug activation (immuno-enzymosomes). The enzyme beta-glucuronidase, capable of activating the prodrug epirubicin-glucuronide (epi-glu), was coupled to the external surface of immunoliposomes directed towards ovarian cancer cells. A significant increase in cytotoxicity of the prodrug epi-glu was shown when the in vitro cultured cancer cells were pretreated with these immuno-enzymosomes.
MeSH terms
-
Antibodies, Monoclonal
-
Cell Division / drug effects
-
Cell Line
-
Drug Carriers
-
Epirubicin / analogs & derivatives*
-
Epirubicin / metabolism
-
Epirubicin / toxicity*
-
Female
-
Glucuronates / metabolism*
-
Glucuronates / toxicity
-
Glucuronidase / metabolism*
-
Humans
-
Immunoglobulin Fab Fragments
-
Liposomes
-
Ovarian Neoplasms
-
Prodrugs / metabolism*
-
Prodrugs / toxicity
-
Tumor Cells, Cultured
Substances
-
Antibodies, Monoclonal
-
Drug Carriers
-
Glucuronates
-
Immunoglobulin Fab Fragments
-
Liposomes
-
Prodrugs
-
epidoxorubicin glucuronide
-
Epirubicin
-
Glucuronidase